BioSpace News Archive

UCB announced new Phase 2b data on the company’s key pipeline molecule, bimekizumab, that showed improvements in a range of important health-related domains and general well-being for patients with active ankylosing spondylitis.ii Results from this study, which evaluated multiple treatment doses, were shared for the first time today at the Annual European Congress of Rheumatology, in Madrid.

93% overall response (13 of 14 patients) and 71% complete response rates (10 of 14 patients) in follicular lymphoma grades 1 to 3a treated with REGN1979 5 mg to 320 mg

Vancouver-based brand expands nationwide retail presence

Aura Biosciences announced that interim clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the European Society of Ophthalmology 2019 Congress being held June 13-16, 2019, in Nice, France.

Dr. Reddy’s Laboratories Ltd. announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC, pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® 3 mg and TOSYMRA™ 10 mg, which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC.

Flexible multi-channel digitizer with high channel density and open FPGA

Study presented at 6th Global Forum on Nicotine contrasts exhaled toxicants in vapor products versus combustible cigarettes

OneFifteen celebrates its grand opening in Dayton, Ohio -- a city once known for its rich history of innovation, but now at the center of the national opioid epidemic -- with the goal to reduce opioid overdose deaths and contribute to the vitality and well-being of the community

In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin (HbS) was reduced to ≤50 percent of total Hb

BerGenBio ASA presents data showing significant efficacy in a Phase II clinical trial evaluating bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with low-dose cytarabine as a potential new treatment regimen for AML patients unfit for intensive therapy.